Innovation Efforts Offer A Way To Change FDA's Views On Risk, Industry Says
This article was originally published in The Gray Sheet
Executive Summary
FDA should put more emphasis on product benefits and patients' willingness to take on risk in pre-market reviews of particularly innovative devices, industry participants argued during an agency workshop last week.